within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05B_AntiParathyroidAgents.H05BA03_CalcitoninHumanSynthetic;

model CalcitoninHumanSynthetic
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.555555555555556e-05,
    adminDuration = 600,
    adminMass = 0.1 / 1000000,
    adminCount = 1,
    Vd = 0.00015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0002,
    k12 = 7.77777777777778e-06,
    k21 = 7.77777777777778e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CalcitoninHumanSynthetic</td></tr><tr><td>ATC code:</td><td>H05BA03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.15</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.8</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Calcitonin (human synthetic) is a peptide hormone analog of endogenous human calcitonin. It is primarily used for the treatment of hypercalcemia, Paget's disease of bone, and postmenopausal osteoporosis. It is approved for clinical use, but its use has decreased with the development of newer osteoporosis medications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H05BA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CalcitoninHumanSynthetic;
